Vanishing Twin Syndrome
- Author: Ann L Anderson-Berry, MD, PhD; Chief Editor: Christine Isaacs, MD more...
Vanishing twin syndrome, first described by Stoeckel in 1945, is the identification of a multifetal gestation with subsequent disappearance of one or more fetuses. The rate of multifetal gestation at conception is higher than the incidence noted at birth. Vanishing twin syndrome has been diagnosed more frequently since the use of ultrasonography in early pregnancy.[2, 3] In vitro fertilization techniques have improved the understanding of vanishing twin syndrome because these pregnancies are closely monitored, and the number of implanted fertilized eggs is known.
In vanishing twin syndrome, there may be complete reabsorption of a fetus, formation of a fetus papyraceus (ie, a "mummified" or compressed fetus), or development of a subtle abnormality on the placenta such as a cyst, subchorionic fibrin, or amorphous material.
The timing of this event significantly affects the outcome of the viable twin and the maternal complications. For example, if the event occurs during the second half of pregnancy, the fetus could develop cerebral palsy or cutis aplasia, and the mother could develop preterm labor, infection, puerperal hemorrhage, consumptive coagulopathy, or obstruction of labor.[6, 7]
Abnormalities that result in the disappearance of a fetus usually appear to be present from early in development rather than occurring from an acute insult. Placental or fetal analysis frequently reveals chromosome abnormalities. These abnormalities include diploidy, triploidy, and alternate sex chromosome results on placental pathology, skin biopsies, and chorionic villus sampling.[8, 9, 10, 11] Study findings of the viable twin chromosomes in these reports are normal. Therefore, it is thought that the vanished twin had a chromosomal abnormality resulting in disappearance.
Research from a European series of pregnancies associated with assisted reproductive technology (ART) show that 10-15% of singleton births were initially twin gestations.
International prevalence is similar to that of the United States.
Maternal first-trimester morbidity
Morbidity when vanishing twin syndrome occurs during the first trimester is limited. The mother is most likely to develop mild vaginal bleeding and cramping. If the event occurs later in the first trimester, morbidity may be similar to that of the second and third trimesters.
Maternal morbidity in the second and third trimesters
Maternal complications include premature labor, infection from a retained fetus, severe puerperal hemorrhage, consumptive coagulopathy, and obstruction of labor by a low-lying fetus papyraceus causing dystocia and leading to a cesarean delivery.
The diagnosis of vanishing twin in a pregnancy significantly increases both preterm (< 37 gestational weeks) and very preterm (< 32 gestational weeks) births.
Fetal morbidity and mortality
In addition to loss of a twin, the surviving fetus has an increased risk of cerebral palsy, particularly if vanishing twin syndrome occurred during the second half of pregnancy.
Other forms of morbidity reported in the surviving twin are aplasia cutis or areas of skin necrosis. In twins connected through vascular connection by placental anastomoses, temporary hypotension in the surviving twin at the time of fetal demise of the vanishing twin leads to poor perfusion and skin necrosis.
Singleton pregnancies that were reduced to singleton because of vanishing twin syndrome are more likely to be delivered preterm (35.1 vs 38.2 wk, P =0001). These rates of preterm delivery are similar to twin IVF pregnancies (23%). In one series, singletons remaining after a vanishing twin event were associated with very premature birth (< 32 wk estimated gestational age).
Low birth weight/small for gestational age
Singleton pregnancies that were reduced to singleton because of vanishing twin syndrome are at higher risk for growth restriction (32.6% vs 16.3% of control IVF singleton pregnancies). Risks associated with intrauterine growth restriction include increased morbidity and mortality in the neonatal period and increased rates of hospitalization in the neonatal intensive care unit.
Researchers proposed that vanishing twin syndrome could result in spastic cerebral palsy in the remaining twin. (Cerebral palsy is the most common hypothesized pathological clinical sequela in the viable twin.)
A possible mechanism is the transfusion of thromboplastic proteins from the vanishing twin to the surviving twin, leading to disseminated intravascular coagulation (DIC). Researchers hypothesize that DIC results from reverse blood flow from the macerated twin to the viable twin, thus carrying thromboplastins into the circulation. This large thromboplastin load is hypothesized to lead to a state of DIC in the viable twin, which then leads to intrauterine central nervous system damage.
Another proposed mechanism for central nervous system damage involves large amounts of blood loss from the surviving twin to the low resistance system of the vanishing twin through placental anastomoses. This transfusion could cause wide fluctuation in intravascular pressures, leading to intraventricular hemorrhage that results in cerebral palsy.
Cerebral impairment in the survivor has also been linked to confirmed cases of vanishing twin with impairment on the Griffiths Mental and Developmental Scales and Optimality score (relative risk 6.1 p=0.03).
Associated congenital anomalies
A link in children with cerebral palsy and other congenital anomalies is possible. In one series, the relative risk for congenital malformations, including microcephaly, isolated hydrocephaly, eye, cleft lip/palate, and cardiac anomalies, increased over baseline from relative risk 3.1-116 (95% CI, 1.9-4.8 to 84 to 162.3; P< 0.01 to P< 0.0001) depending on the specific defect. These anomalies are postulated to be due in part to perturbations in fetal flow in the surviving twin at the time of loss of the vanishing twin.
The mechanism of development of cutis aplasia is most likely vascular. There is thought to be decreased perfusion to the affected area at the time of demise of the vanished twin. Most case reports include a fetus papyraceous as the vanished twin.[13, 20]
Preterm birth of the surviving twin has been described with a 2.3-fold increased risk and a mortality rate that is 3-fold increased.[21, 22]
The surviving singleton infant after a twin vanishes has been shown to have a lower birth weight (mean difference, 368 g) than singleton pregnancies.
No predilection for any race has been reported.
No predilection for either sex has been reported in the vanishing twin.
Researchers report more cases in women older than 30 years. Advanced maternal age is also a recognized risk factor for fetal and placental chromosome abnormalities.
Landy HJ, Weiner S, Corson SL, et al. The "vanishing twin": ultrasonographic assessment of fetal disappearance in the first trimester. Am J Obstet Gynecol. 1986 Jul. 155(1):14-9. [Medline].
Saidi MH. First-trimester bleeding and the vanishing twin. A report of three cases. J Reprod Med. 1988 Oct. 33(10):831-4. [Medline].
Sulak LE, Dodson MG. The vanishing twin: pathologic confirmation of an ultrasonographic phenomenon. Obstet Gynecol. 1986 Dec. 68(6):811-5. [Medline].
Sampson A, de Crespigny LC. Vanishing twins: the frequency of spontaneous fetal reduction of a twin pregnancy. Ultrasound Obstet Gynecol. 1992 Mar 1. 2(2):107-9. [Medline].
Landy HJ, Keith LG. The vanishing twin: a review. Hum Reprod Update. 1998 Mar-Apr. 4(2):177-83. [Medline].
Yoshida K, Soma H. Outcome of the surviving cotwin of a fetus papyraceus or of a dead fetus. Acta Genet Med Gemellol (Roma). 1986. 35(1-2):91-8. [Medline].
Yoshida K, Matayoshi K. A study on prognosis of surviving cotwin. Acta Genet Med Gemellol (Roma). 1990. 39(3):383-8. [Medline].
Callen DF, Fernandez H, Hull YJ, Svigos JM, Chambers HM, Sutherland GR. A normal 46,XX infant with a 46,XX/69,XXY placenta: a major contribution to the placenta is from a resorbed twin. Prenat Diagn. 1991 Jul. 11(7):437-42. [Medline].
Reddy KS, Petersen MB, Antonarakis SE, Blakemore KJ. The vanishing twin: an explanation for discordance between chorionic villus karyotype and fetal phenotype. Prenat Diagn. 1991 Sep. 11(9):679-84. [Medline].
Lloveras E, Lecumberri JM, Perez C, et al. A female infant with a 46,XX/48,XY, +8, +10 karyotype in prenatal diagnosis: a 'vanishing twin' phenomenon?. Prenat Diagn. 2001 Oct. 21(10):896-7. [Medline].
Verstraete L, Costa JM, Chantot-Bastaraud S, Siffroi JP, Fiori O, Uzan S. Finding a single XY cell among XX cells in amniotic fluid by FISH: a possible consequence of a vanishing male twin?. Prenat Diagn. 2007 Jan. 27(1):85-6. [Medline].
Pharoah PO, Cooke RW. A hypothesis for the aetiology of spastic cerebral palsy--the vanishing twin. Dev Med Child Neurol. 1997 May. 39(5):292-6. [Medline].
Classen DA. Aplasia cutis congenita associated with fetus papyraceous. Cutis. 1999 Aug. 64(2):104-6. [Medline].
Almog B, Levin I, Wagman I, Kapustiansky R, Lessing JB, Amit A, et al. Adverse obstetric outcome for the vanishing twin syndrome. Reprod Biomed Online. 2010 Feb. 20(2):256-260. [Medline].
Sazonova A, Kallen K, Thurin-Kjellberg A, Wennerholm UB, Bergh C. Factors affecting obstetric outcome of singletons born after IVF. Hum Reprod. 2011 Oct. 26(10):2878-86. [Medline].
Shebl O, Ebner T, Sommergruber M, Sir A, Tews G. Birth weight is lower for survivors of the vanishing twin syndrome: a case-control study. Fertil Steril. 2008 Aug. 90(2):310-4. [Medline].
Benirschke K. Intrauterine death of a twin: mechanisms, implications for surviving twin, and placental pathology. Semin Diagn Pathol. 1993 Aug. 10(3):222-31. [Medline].
Anand D, Platt MJ, Pharoah PO. Vanishing twin: a possible cause of cerebral impairment. Twin Res Hum Genet. 2007 Feb. 10(1):202-9. [Medline].
Pharoah PO. Prevalence and pathogenesis of congenital anomalies in cerebral palsy. Arch Dis Child Fetal Neonatal Ed. 2007 Nov. 92(6):F489-93. [Medline].
Maccario S, Fasolato V, Brunelli A, Martinelli S. Aplasia cutis congenita: an association with vanishing twin syndrome. Eur J Dermatol. 2009 Jul-Aug. 19(4):372-4. [Medline].
Pinborg A, Lidegaard O, Andersen AN. The vanishing twin: a major determinant of infant outcome in IVF singleton births. Br J Hosp Med (Lond). 2006 Aug. 67(8):417-20. [Medline].
Evron E, Sheiner E, Friger M, Sergienko R, Harlev A. Vanishing twin syndrome: is it associated with adverse perinatal outcome?. Fertil Steril. 2015 May. 103 (5):1209-14. [Medline].
Sarhan A, Beydoun H, Jones HW Jr, Bocca S, Oehninger S, Stadtmauer L. Gonadotrophin ovulation induction and enhancement outcomes: analysis of more than 1400 cycles. Reprod Biomed Online. 2011 Aug. 23(2):220-6. [Medline].
Jauniaux E, Elkazen N, Leroy F, et al. Clinical and morphologic aspects of the vanishing twin phenomenon. Obstet Gynecol. 1988 Oct. 72(4):577-81. [Medline].
Rudnicki M, Vejerslev LO, Junge J. The vanishing twin: morphologic and cytogenetic evaluation of an ultrasonographic phenomenon. Gynecol Obstet Invest. 1991. 31(3):141-5. [Medline].
Pinborg A. IVF/ICSI twin pregnancies: risks and prevention. Hum Reprod Update. 2005 Nov-Dec. 11(6):575-93. [Medline].
Bryan E. Loss in higher multiple pregnancy and multifetal pregnancy reduction. Twin Res. 2002 Jun. 5(3):169-74. [Medline].
De Pascalis L, Monti F, Agostini F, Fagandini P, La Sala GB, Blickstein I. Psychological vulnerability of Singleton children after the 'vanishing' of a co-twin following assisted reproduction. Twin Res Hum Genet. 2008 Feb. 11(1):93-8. [Medline].
Chasen ST, Perni SC, Predanic M, Kalish RB, Chervenak FA. Does a "vanishing twin" affect first-trimester biochemistry in Down syndrome risk assessment?. Am J Obstet Gynecol. 2006 Jul. 195(1):236-9. [Medline].
Abbas A, Johnson M, Bersinger N, Nicolaides K. Maternal alpha-fetoprotein levels in multiple pregnancies. Br J Obstet Gynaecol. 1994 Feb. 101(2):156-8. [Medline].
Kelly MP, Molo MW, Maclin VM, Binor Z, Rawlins RG, Radwanska E. Human chorionic gonadotropin rise in normal and vanishing twin pregnancies. Fertil Steril. 1991 Aug. 56(2):221-4. [Medline].
Gjerris AC, Loft A, Pinborg A, Christiansen M, Tabor A. The effect of a 'vanishing twin' on biochemical and ultrasound first trimester screening markers for Down's syndrome in pregnancies conceived by assisted reproductive technology. Hum Reprod. 2009 Jan. 24(1):55-62. [Medline].
Gjerris AC, Tabor A, Loft A, Christiansen M, Pinborg A. First trimester prenatal screening among women pregnant after IVF/ICSI. Hum Reprod Update. 2012 Jul. 18(4):350-9. [Medline].
Blumenfeld Z, Dirnfeld M, Abramovici H, et al. Spontaneous fetal reduction in multiple gestations assessed by transvaginal ultrasound. Br J Obstet Gynaecol. 1992 Apr. 99(4):333-7. [Medline].
Lau WC, Rogers MS. Fetus papyraceous: an unusual cause of obstructed labour. Eur J Obstet Gynecol Reprod Biol. 1999 Sep. 86(1):109-11. [Medline].
Pinborg A, Lidegaard O, Freiesleben NC, Andersen AN. Vanishing twins: a predictor of small-for-gestational age in IVF singletons. Hum Reprod. 2007 Oct. 22(10):2707-14. [Medline].
Shebl O, Ebner T, Sommergruber M, Sir A, Tews G. Birth weight is lower for survivors of the vanishing twin syndrome: a case-control study. Fertil Steril. 2007 Oct 9. [Medline].
Anand D, Platt MJ, Pharoah PO. Comparative development of surviving co-twins of vanishing twin conceptions, twins and singletons. Twin Res Hum Genet. 2007 Feb. 10(1):210-5. [Medline].
Pharoah PO. Neurological outcome in twins. Semin Neonatol. 2002 Jun. 7(3):223-30. [Medline].
Pinborg A, Lidegaard O, la Cour Freiesleben N, Andersen AN. Consequences of vanishing twins in IVF/ICSI pregnancies. Hum Reprod. Oct 2005. 20(10):2821-9. [Medline].